REFERENCES
- Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC, Fuchs PC. Cefditoren in vitro activity and spectrum: a review of inter-national studies using reference methods. Diagn Microbiol Infect Dis. 2001; 41(1-2):1–14.
- Mandell LA. Antimicrobial resistance and treatment of community-acquired pneumonia. Clin Chest Med. 2005; 26 (1): 57–64.
- Clark CL, Nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR, et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother. 2002; 50 (1): 33–41.
- Lee MY, Ko KS, Oh WS, Park S, Lee JY, Baek JY et al. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents. 2006; 28 (1): 14–8.
- Seral C, Suarez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P. et al. In vitro activity of cefditoren and other an-timicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis. 2008; 62 (2): 210–5.
- Stefani S, Mezzatesta ML, Fadda G, Mattina R, Pali) G, Rossano F, et al. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother. 2008; 20 (5): 561–569.
- Clinical and Laboratory Standards Institute (CLSI). Per-formance standards for antimicrobial susceptibility testing: sev-enteenth informational supplement. CLSI document M100-S17. CLSI, Wayne, Pennsylvania 2007.
- Cascone C, Mezzatesta ML, Santagati M, Cafiso V, Nico-letti G, Stefani S. Activity of telithromycin against multi-drug resistant Streptococcus pneumoniae and molecular characterization of macrolide and tetracycline resistance deter-minants. J Chemother. 2005; 17 (5): 502–508.
- Swenson JM, Peterson L. (ed.): Special phenotypic meth-ods for detecting antibacterial resistance. Washington DC: ASM Press; 1999.
- Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Microbiol Infect Dis. 2000; 37: 187–193.
- Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Mi-crobiol Infect Dis. 2000; 37 (2): 99–105.
- Spangler SK, Jacobs MR, Appelbaum PC. Time-kill Studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other 13-lactams. J Antimicrob Chemother. 1997; 39: 141–148.
- Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y, et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae Penicillin-Binding Protein 2X: Struc-tural basis for its high antimicrobial activity. Antimicrob Agents Chemother. 2007; 51 (11): 3902–3907.
- Stephens DS, Farley MM. Pathogenic events during in-fection of the human nasopharynx with Neisseria men ingitidis and Haemophilus influenzae. Rev Infect Dis. 1991; 13 (1): 22–33.
- Swords WE, Ketterer MR, Shao J, Campbell CA, Weiser JN, Apicella MA. Binding of the non-typable Haemophilus influenzae lipooligosaccharide to the PAF receptor initiates host cell signalling. Cell Microbiol. 2001; 3 (8): 525–36.
- Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother. 2006; 58 (4): 873–7.
- Karlowsky JA, Critchley IA, Draghi DC, Jones ME, Thornsberry C, Sahm DF. Activity of cefditoren against beta-lac-tamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis. 2002; 42 (1): 53–8.
- Cafini F, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M et al. Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity. Eur J Clin Microbiol Infect Dis. 2008; 26.
- Fenoll A, Giménez MJ, Robledo O, Coronel P, Gimeno M, Casal J et al. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to peni-cillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents. 2007; 29 (2): 224-6.